(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of Duchenne muscular dystrophy in patients 4 years of age and older.
The company noted that AGAMREE was the first medicinal product for Duchenne muscular dystrophy (DMD) to have received approval in the EU, US, and UK.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
